NCT06830109 Nasal Obstruction With Oxymetazoline and Corticosteroids
| NCT ID | NCT06830109 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Washington University School of Medicine |
| Condition | Nasal Obstruction |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2024-10-15 |
| Primary Completion | 2026-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 80 participants in total. It began in 2024-10-15 with a primary completion date of 2026-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to examine the efficacy and safety of commination oxymetazoline/intranasal steroids for long-term management of chronic nasal obstruction that is recalcitrant to the current standard of care. The investigators hypothesize that combination treatment with oxymetazoline and intranasal corticosteroid spray will provide a larger reduction in nasal obstruction than intranasal corticosteroid alone for patients suffering from chronic nasal obstruction, and there will not be occurrences of rhinitis medicamentosa.
Eligibility Criteria
Inclusion Criteria: 1. males and females ages 18 years or older 2. have a history of nasal obstruction 3. have failed a trial of topical steroids (that included at least 1 month of daily use) 4. ability to read, write, and understand English 5. either do not desire surgery or are poor surgical candidates due to medical comorbidities. 6. Patients who have had prior use of oxymetazoline or other nasal decongestants are eligible for the study but must have stopped usage 4 weeks prior to randomization. 1. Must be willing to stop using any other nasal sprays, besides saline, and oral decongestants. Exclusion Criteria: 1. Any history of sinonasal mass/tumor 2. Any history of nasal polyps 3. a known history of chronic sinusitis 4. an allergy to oxymetazoline 5. or who have any medical contraindication to oxymetazoline use, such as pulmonary hypertension.
Contact & Investigator
Nyssa F Farrell, MD
PRINCIPAL INVESTIGATOR
Washington University School of Medicine
Frequently Asked Questions
Who can join the NCT06830109 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Nasal Obstruction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06830109 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06830109 currently recruiting?
Yes, NCT06830109 is actively recruiting participants. Contact the research team at nyssa.farrell@wustl.edu for enrollment information.
Where is the NCT06830109 trial being conducted?
This trial is being conducted at St Louis, United States.
Who is sponsoring the NCT06830109 clinical trial?
NCT06830109 is sponsored by Washington University School of Medicine. The principal investigator is Nyssa F Farrell, MD at Washington University School of Medicine. The trial plans to enroll 80 participants.